

TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 11/27/89 AND 12/08/89

Name of acquiring person, Name of acquired person, Name of acquired entity	PMN number	Date terminated
John T. Melin Western Athletic Clubs, Inc./ Western Athletic Properties.....		
First Chicago Corporation, The Goldman Sachs Group, L.P. Skyhigh Corporation.....	90-0441	12/04/89
E-L Financial Corporation Limited, Guardian Royal Exchange plc, GRENEL Financial Corporation.....	90-0444	12/04/89
Harcourt Brace Jovanovich, Inc., American Pioneer, Inc., American Pioneer Life Insurance Company and American.....	90-0448	12/04/89
Norwest Corporation, Barclays PLC, Barclays Bank of Delaware, National Association.....	90-0457	12/04/89
PepsiCo, Inc., Alan W. Lee, Tri-L Pizza Huts, Inc.....	90-0458	12/04/89
E. I. du Pont de Nemours and Company, Freeport-McMoRan Inc., FMP Operating Company, a Limited Partnership.....	90-0467	12/04/89
18th Street Associates, Sears, Roebuck and Co., Sears Catalog Distribution Center.....	90-0468	12/04/89
Leonard S. Mandor, c/o Concord Assets Group, Inc., Milestone Properties, Inc., Milestone Properties, Inc.....	90-0470	12/04/89
PepsiCo, Inc., Peter C. Toigo, Winchell's Donut House Operating Company, L.P.....	90-0472	12/04/89
Charterhouse Equity Partners, L.P., Torstar Corporation, Miles Kimball Company.....	90-0473	12/04/89
All Nippon Airways Co., Ltd., Aoki Corporation, The Westin Hotel, Washington, D.C.....	90-0484	12/04/89
Sonat Inc., Carlile and Howell, Inc., Carlile and Howell, Inc.....	90-0485	12/04/89
International Business Machines Corporation, Dayton Partners (Ohio Partnership) Dayton & Associates Partnerships.....	90-0488	12/04/89
George Macomber, Sears, Roebuck and Co., Sears Catalog Distribution Center.....	90-0491	12/04/89
Dow Jones & Company, Inc., American Telephone and Telegraph Company, AT&T Development Corporation.....	90-0511	12/04/89
VAALCO Energy Inc., The Australian Gas Light Company, TMOG Petroleum Inc., c/o Corporation Trust Company.....	90-0513	12/04/89

TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 11/27/89 AND 12/08/89—Continued

Name of acquiring person, Name of acquired person, Name of acquired entity	PMN number	Date terminated
Nacolah Holding Corporation, Amoco Corporation, Amoco Life Insurance Company.....	90-0518	12/04/89
Richard Fanslow, Greenbrier Acquisition, Inc., Greenbrier Acquisition, Inc.....	90-0520	12/04/89
Comdisco, Inc., Centel Corporation, Centel Credit Corporation.....	90-0539	12/04/89
Comdisco, Inc., North American Computer Equipment, Inc., North American Computer Equipment, Inc.....	90-0540	12/04/89
PacificCorp, UtiliCorp United Inc, PSI, Inc.....	90-0542	12/04/89
PacificCorp William T. Bright, Land Use Corporation, Bright Coal Corporation.....	90-0367	12/04/89
Ashland Oil Inc., Olin Corporation, Olin Corporation.....	90-0396	12/05/89
Hyperion Partners, L.P., The Travelers Corporation, Travelers Mortgage Services, Inc.....	90-0398	12/05/89
The Louisiana Land and Exploration Company, The British Petroleum Company p.l.c., BP Exploration Inc.....	90-0401	12/05/89
Merrill Lynch & Co., Inc., Bitrix N.V., Pangborn Holdings, Inc.....	90-0420	12/05/89
Merrill Lynch & Co., Inc., Daniel J. Sullivan, Pangborn Holdings, Inc.....	90-0421	12/05/89
Brierley Investments Limited, La Quinta Motor Inns, Inc., La Quinta Motor Inns, Inc.....	90-0438	12/05/89
Sumitomo Realty & Development Co., Ltd., Liberty/Manhattan Beach Limited Partnership, The Residence Inn By Marriott.....	90-0453	12/05/89
Mr. Yoshiyuki Nakayama, Liberty/Manhattan Beach Limited Partnership, The Residence Inn by Marriott, Inc.....	90-0454	12/05/89
Canyon Resources Corporation, Addington Resources, Inc., Addwest Gold, Inc.....	90-0482	12/05/89
Sunshine Mining Company, Montana Reserves Company, Montana Reserves Company.....	90-0483	12/05/89
Sony Corporation, Time Warner Inc., Lot, Inc.....	90-0492	12/05/89
Center for Independent Living, Beverly Enterprises, Inc., Beverly Enterprises—Massachusetts, Inc.....	90-0347	12/06/89

TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 11/27/89 AND 12/08/89—Continued

Name of acquiring person, Name of acquired person, Name of acquired entity	PMN number	Date terminated
J. B. Poindexter, Elton E. Mountz, Morgan Trailer Mfg. Co.....	90-0431	12/06/89
Toyota Motor Corporation, Robert J. Bodine, Bodine Aluminum Inc., Lucile Investment Company, Inc.....	90-0474	12/06/89
TriMas Corporation, Charles O. Hiler & Son, Inc., Charles O. Hiler & Son, Inc.....	90-0493	12/06/89
TriMas Corporation, Accurate Castings, Inc., Accurate Castings, Inc.....	90-0507	12/06/89
Syntrex Incorporated, Harris Corporation, Lanier Business System Division.....	90-0564	12/06/89
Burnham Pacific Properties, Inc., Pan Pacific Development Corporation, Pan Pacific Development (California), Inc.....	90-0660	12/06/89
The 1964 Simmons Trust, Lockheed Corporation, Lockheed Corporation.....	90-0469	12/07/89
Societe de Diffusion Internationale Agro-Alimentaire, Borden, Inc., Meadow Gold Dairies, Inc.....	90-0489	12/07/89
Cardinal Communications, Inc., Donald G. Jones, Star Midwest Indiana Group.....	90-0523	12/07/89

FOR FURTHER INFORMATION CONTACT:
Sandra M. Peay, Federal Trade Commission, Contact Representative, Premerger Notification Office, Bureau of Competition, Room 303, Washington, DC 20580, (202) 326-3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 89-29471 Filed 12-18-89; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 89N-0519]

Drug Export; Antihemophilic Factor (Human), Liquid Heat Treated

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Armour Pharmaceutical Co. has filed an application requesting approval for the export of the biological product Antihemophilic Factor (Human), Liquid Heat Treated to Belgium, Denmark, The Federal Republic of Germany, France, Ireland, Italy, Luxembourg, The Netherlands, Portugal, Spain, and The United Kingdom.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Boyd Fogle, Jr., Inspections and Surveillance Staff (HFB-120), Center for Biologics Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8191.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Armour Pharmaceutical Co., Suite 200, 920A Harvest Dr., Blue Bell, PA, 19422, has filed an application requesting approval for the export of the biological product Antihemophilic Factor (Human), Liquid Heat Treated, to Belgium, Denmark, The Federal Republic of Germany, France, Ireland, Italy, Luxembourg, The Netherlands, Portugal, Spain, and The United Kingdom. Antihemophilic Factor (Human), Liquid Heat Treated is indicated for treatment of classical hemophilia (Hemophilia A). The application was received and filed in the Center for Biologics Evaluation and Research on November 27, 1989,

which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by December 29, 1989, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Biologics Evaluation and Research (21 CFR 5.44).

Dated: December 4, 1989.

Thomas S. Bozzo,

Director, Office of Compliance Center for Biologics Evaluation and Research.

[FR Doc. 89-29442 Filed 12-18-89; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 89C-0480]

CIBA Vision Corp.; Filing of Color Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba Vision Corp. has filed a petition proposing that the color additive regulations be amended to provide for the safe use of six vinyl sulfone reactive dyes to color contact lenses prepared from a copolymer that is the reaction product of the dye and a polyvinyl alcohol/methyl methacrylate copolymer. The dyes are as follows:

(1) C.I. Reactive Black 5 (2,7-naphthalenedisulfonic acid, 4-amino-5-hydroxy-3,6-bis(4-((2-(sulfooxy)ethyl)sulfonyl)-phenyl)azo)-, tetrasodium salt, CAS Reg. No. 17095-24-8);

(2) C.I. Reactive Blue 21 (cooper, (29*H*,31*H*-phthalocyanina(2-)-*N*²⁹, *N*³⁰, *N*³¹, *N*³²)-, sulfo(4-((2-(sulfooxy)ethyl)sulfonyl)phenyl)amino) sulfonyl derivatives, CAS Reg. No. 73049-92-0);

(3) C.I. Reactive Orange 78 (2-naphthalenesulfonic acid, 7-(acetylamino)-4-hydroxy-3-((4-((2-(sulfooxy)ethyl)sulfonyl)phenyl)azo)-, CAS Reg. No. 68189-39-9);

(4) C.I. Reactive Yellow 15 (benzenesulfonic acid, 4-(4,5-dihydro-4-((2-methoxy-5-methyl-4-((2-(sulfooxy)ethyl)sulfonyl)azo)-3-methyl-5-oxo-1*H*-pyrazol-1-yl)-, CAS Reg. No. 60958-41-0);

(5) C.I. Reactive Blue No. 19 (2-anthracenesulfonic acid, 1-amino-9,10-dihydro-9,10-dioxo-4-((3-((2-(sulfooxy)ethyl)sulfonyl)phenyl)amino)-, disodium salt, CAS Reg. No. 2580-78-1);

(6) C.I. Reactive Red 180 (5-(benzoylamino)-4-hydroxy-3-((1-sulfo-6-((2-sulfooxy)ethyl)sulfonyl)-2-naphthalenyl)azo)-2,7-naphthalenedisulfonic acid, tetrasodium salt, CAS Reg. No. 98114-32-0).

FOR FURTHER INFORMATION CONTACT: Sandra L. Varner, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 706(d)(1) (21 U.S.C. 376(d)(1))), notice is given that a petition (CAP 9C0217) has been filed by Ciba Vision Corp., P.O. Box 105069, Atlanta, GA 30348, proposing that 21 CFR Part 73 of the color additive regulations be amended to provide for the safe use of six vinyl sulfone reactive dyes to color contact lenses prepared from a copolymer that is the reaction product of the dye and a polyvinyl alcohol/methyl methacrylate copolymer. The dyes are as follows:

(1) C.I. Reactive Black 5 (2,7-naphthalenedisulfonic acid, 4-amino-5-hydroxy-3,6-bis(4-((2-(sulfooxy)ethyl)sulfonyl)-phenyl)azo)-, tetrasodium salt, CAS Reg. No. 17095-24-8);

(2) C.I. Reactive Blue 21 (cooper, (29*H*,31*H*-phthalocyaninato(2-)-*N*²⁹, *N*³⁰, *N*³¹, *N*³²)-, sulfo(4-((2-(sulfooxy)ethyl)sulfonyl)phenyl)amino) sulfonyl derivatives, CAS Reg. No. 73049-92-0);

(3) C.I. Reactive Orange 78 (2-naphthalenesulfonic acid, 7-(acetylamino)-4-hydroxy-3-((4-((2-(sulfooxy)ethyl)sulfonyl)phenyl)azo)-, CAS Reg. No. 68189-39-9);

(4) C.I. Reactive Yellow 15 (benzenesulfonic acid, 4-(4,5-dihydro-4-((2-methoxy-5-methyl-4-((2-(sulfooxy)ethyl)sulfonyl)azo)-3-methyl-5-oxo-1*H*-pyrazol-1-yl)-, CAS Reg. No. 60958-41-0);

(5) C.I. Reactive Blue No. 19 (2-anthracenesulfonic acid, 1-amino-9,10-

dihydro-9,10-dioxo-4-((3-((2-(sulfooxy)ethyl)sulfonyl)phenyl)amino)-, disodium salt, CAS Reg. No. 2580-78-1); and

(6) C.I. Reactive Red 180 (5-(benzoylamino)-4-hydroxy-3-((1-sulfo-6-((2-(sulfooxy)sulfonyl)-2-naphthalenyl)azo-2,7-naphthalenedisulfonic acid, tetrasodium salt, CAS Reg. No. 98114-32-0).

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: December 4, 1989.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 89-29372 Filed 12-18-89; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 89F-0453]

PPG Industries, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that PPG Industries, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of a *N, N, N, N', N', N'*-hexakis(methoxymethyl)-1,3,5-triazine-2,4,6-triamine polymer with stearyl alcohol, α -octadecenyl- Ω -hydroxypoly(oxy-1,2-ethanediyl) and alkyl ($C_{20}+$) alcohols as a component of paper and paperboard in contact with aqueous food.

FOR FURTHER INFORMATION CONTACT: Edward J. Machuga, Center for Food Safety and Applied Nutrition (HFF-335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 9B4172) has been filed by PPG Industries, Inc., Pittsburgh, PA 15146, proposing that § 176.170 *Components of paper and paperboard in contact with aqueous and fatty foods* (21 CFR 176.170) be amended to provide for the safe use of a *N, N, N, N', N', N'*-hexakis(methoxymethyl)-1,3,5-triazine-2,4,6-triamine polymer with stearyl

alcohol, α -octadecenyl- Ω -hydroxypoly(oxy-1,2-ethanediyl) and alkyl ($C_{20}+$) alcohols as a component of paper and paperboard in contact with aqueous food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: December 11, 1989.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 89-29443 Filed 12-18-89; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 89N-0518]

Drug Export: HTLV-1 Elisa Test Kit

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Cellular Products, Inc., has filed an application requesting approval for the export of the biological product HTLV-1 Elisa Test Kits to Italy.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Boyd Fogle, Jr., Inspections and Surveillance Staff (HFB-120), Center for Biologics Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-295-8191.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether

the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Cellular Products, Inc., 688 Main St., Buffalo, NY, 14202, has filed an application requesting approval for the export of the biological products HTLV-1 Elisa Test Kits to Italy. HTLV-1 Elisa Test Kit is an enzyme linked immunosorbent assay for the detection of antibodies to Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) in human plasma or serum. The application was received and filed in the Center for Biologics Evaluation and Research on November 6, 1989, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by December 26, 1989, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Biologics Evaluation and Research (21 CFR 5.44).

Dated: December 4, 1989.

Thomas S. Bozzo,

Director, Office of Compliance, Center for Biologics Evaluation and Research.

[FR Doc. 89-29373 Filed 12-18-89; 8:45 am]

BILLING CODE 4160-01-M

Health Resources and Services Administration

National Vaccine Injury Compensation Program List of Petitions Received

AGENCY: Public Health Service, HHS.

ACTION: Notice.